Get to Know Dr. Robert A. Ramirez
Dr. Robert Ramirez earned his degree from the Rutgers Robert Wood Johnson Medical School. He completed his fellowship in hematology and medical oncology at the University of Tennessee Health Science Center, where he served as chief fellow.
In 2015, Ramirez joined the multidisciplinary program at Ochsner Medical Center, which consists of thoracic surgeons, pulmonologists and pathologists. They meet regularly to discuss each patient and design a personalized treatment plan. The program includes an emphasis on lung cancer and pleural mesothelioma plus a widening research department.
Ramirez is board certified in medical oncology and a specialist in internal medicine. He is a member of the American Society of Clinical Oncology, the North American Neuroendocrine Tumor Society and the International Association for the Study of Lung Cancer.
His clinical and research interests include non-small cell and small cell lung cancer, malignant mesothelioma treatment and neuroendocrine tumors of the lung and gastrointestinal tract.
Ramirez is the associate director for cancer research at the Ochsner Health System in New Orleans, and is developing a clinical trial program that is among the country’s finest.
He has spoken extensively on lung cancer, standard chemotherapy for mesothelioma patients and neuroendocrine tumors at national and international meetings.
Specialties of Dr. Robert A. Ramirez
- Pleural and lung cancer
Dr. Robert A. Ramirez’s Experience and Medical Education
- Ochsner Medical Center
- University of Tennessee Health Science Center (Fellowship)
- Cooper University Hospital (Residency)
- Rutgers Robert Wood Johnson Medical School (D.O.)
- Board certified in medical oncology
Awards and Certifications
- Resident/Fellow Research Mentor of the Year (2017)
- Academic Achievement in Biology (1997)
Publications of Dr. Robert A. Ramirez
- Landry, J.P. et al. (2020, November 12). Management of Appendiceal Neuroendocrine Tumors: Beyond Tumor Size. Journal of Cancer Immunology.
- Landry, J.P. et al. (2020, July 20). Management of Appendiceal Neuroendocrine Tumors: Metastatic Potential of Small Tumors. Gastrointestinal Oncology.
- Bockorny, B. et al. (2020, May 25). BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nature Medicine.
Thank you for your feedback. Would you like to speak with a Patient Advocate?